Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108147
Title:
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
Authors:
Thatcher, Nick; Dazzi, H; Johnson, Richard J; Russell, S; Ghosh, Anna K; Moore, M; Chadwick, G; Craig, R D
Abstract:
Recombinant interleukin-2 (rIL-2) was used to treat 31 patients with progressing metastatic malignant melanoma. Only three patients had disease confined to non-visceral sites; the median number of organ sites involved was four. The first dose of rIL-2 was given intrasplenically (to stimulate cytotoxic cells in high concentration) via a femoral artery catheter, and four further i.v. doses were given over 6 days. A total of three courses at 21-day intervals was planned. Doses were escalated in 15 patients from 1 x 10(6) to 16.4 x 10(4) Cetus units m-2. The maximum tolerated dose (11.0 x 10(6) U m-2) was used in the other 16 patients. Of the 71 courses, severe but transient toxicity requiring interruption of rIL-2 or additional care occurred on three courses (dyspnoea) and 15 from hypotension, but the patients' performance status improved. Four patients had partial tumour responses although in only one patient did response occur in all sites of disease. However, responses occurred in visceral sites and six patients are alive at 9-16 months. IL-2 is of use in advanced melanoma and does not need complicated ICU facilities.
Affiliation:
Department of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, UK.
Citation:
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study. 1989, 60 (5):770-4 Br J Cancer
Journal:
British Journal of Cancer
Issue Date:
Nov-1989
URI:
http://hdl.handle.net/10541/108147
PubMed ID:
2803954
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorDazzi, Hen
dc.contributor.authorJohnson, Richard Jen
dc.contributor.authorRussell, Sen
dc.contributor.authorGhosh, Anna Ken
dc.contributor.authorMoore, Men
dc.contributor.authorChadwick, Gen
dc.contributor.authorCraig, R Den
dc.date.accessioned2010-07-22T09:38:24Z-
dc.date.available2010-07-22T09:38:24Z-
dc.date.issued1989-11-
dc.identifier.citationRecombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study. 1989, 60 (5):770-4 Br J Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid2803954-
dc.identifier.urihttp://hdl.handle.net/10541/108147-
dc.description.abstractRecombinant interleukin-2 (rIL-2) was used to treat 31 patients with progressing metastatic malignant melanoma. Only three patients had disease confined to non-visceral sites; the median number of organ sites involved was four. The first dose of rIL-2 was given intrasplenically (to stimulate cytotoxic cells in high concentration) via a femoral artery catheter, and four further i.v. doses were given over 6 days. A total of three courses at 21-day intervals was planned. Doses were escalated in 15 patients from 1 x 10(6) to 16.4 x 10(4) Cetus units m-2. The maximum tolerated dose (11.0 x 10(6) U m-2) was used in the other 16 patients. Of the 71 courses, severe but transient toxicity requiring interruption of rIL-2 or additional care occurred on three courses (dyspnoea) and 15 from hypotension, but the patients' performance status improved. Four patients had partial tumour responses although in only one patient did response occur in all sites of disease. However, responses occurred in visceral sites and six patients are alive at 9-16 months. IL-2 is of use in advanced melanoma and does not need complicated ICU facilities.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intra-Arterial-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshInterleukin-2-
dc.subject.meshMale-
dc.subject.meshMelanoma-
dc.subject.meshMiddle Aged-
dc.subject.meshRecombinant Proteins-
dc.subject.meshSplenic Artery-
dc.titleRecombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.